Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Moderna Inc
(NQ:
MRNA
)
65.69
-2.33 (-3.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
Via
ACCESSWIRE
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
May 03, 2023
Via
ACCESSWIRE
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
May 02, 2023
Via
ACCESSWIRE
6 Best Healthcare Stocks to Buy Right Now
April 25, 2023
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat.
Via
MarketBeat
Topics
Economy
Intellectual Property
Exposures
Economy
Intellectual Property
Product Safety
Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
April 20, 2023
Via
ACCESSWIRE
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
April 20, 2023
Via
ACCESSWIRE
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
April 11, 2023
Via
ACCESSWIRE
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
March 10, 2023
Via
ACCESSWIRE
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
April 16, 2023
Via
ACCESSWIRE
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV
April 06, 2023
Via
ACCESSWIRE
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
March 30, 2023
Via
ACCESSWIRE
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
March 24, 2023
Via
ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
March 23, 2023
Via
ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
March 23, 2023
From
Generation Bio Co.; Moderna
Via
GlobeNewswire
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
February 23, 2023
Via
ACCESSWIRE
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
February 17, 2023
Via
ACCESSWIRE
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
March 20, 2023
By Ernest Dela Aglanu, Benzinga
Via
TheNewswire.com
Topics
Death
Economy
Exposures
COVID-19
Death
Economy
Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
March 14, 2023
Via
ACCESSWIRE
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
February 28, 2023
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna to Present at Cowen's 43rd Annual Health Care Conference
February 28, 2023
Via
ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk
February 22, 2023
Via
ACCESSWIRE
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
February 22, 2023
Via
ACCESSWIRE
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
February 16, 2023
Via
ACCESSWIRE
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
February 03, 2023
From
Personalis, Inc.
Via
Business Wire
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
February 02, 2023
Via
ACCESSWIRE
Novavax Shares Jumped in January While Others Slipped
February 01, 2023
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
January 30, 2023
Via
ACCESSWIRE
Mergers and Acquisitions in 2023 Off To A Strong Start
January 26, 2023
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
Via
MarketBeat
Exposures
Product Safety
How Could GSK's RSV Vaccine Change its Valuation?
January 26, 2023
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.
Via
MarketBeat
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.